
K Frank Austen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7159731/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lineage-specific regulation of inducible and constitutive mast cells in allergic airway inflammation. Journal of Experimental Medicine, 2021, 218, .	8.5	42
2	The CysLT ₂ R receptor mediates leukotriene C ₄ -driven acute and chronic itch. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	57
3	The Discovery of Discrete Developmental Pathways Directing Constitutive and Induced Mast Cells in Mice. Journal of Immunology, 2021, 207, 359-361.	0.8	2
4	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. Theranostics, 2020, 10, 10743-10768.	10.0	107
5	AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. Journal of Allergy and Clinical Immunology, 2019, 144, 883-896.	2.9	72
6	Mechanical Skin Injury Promotes Food Anaphylaxis by Driving Intestinal Mast Cell Expansion. Immunity, 2019, 50, 1262-1275.e4.	14.3	158
7	Roles of cysteinyl leukotrienes and their receptors in immune cell-related functions. Advances in Immunology, 2019, 142, 65-84.	2.2	33
8	Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 199-204.	7.1	43
9	Role of Cysteinyl Leukotriene 2 Receptor in Tumor Angiogenesis, Permeability and Metastasis. FASEB Journal, 2019, 33, 489.7.	0.5	0
10	Mentoring: An art and a responsibility. Journal of Allergy and Clinical Immunology, 2018, 141, 880-881.	2.9	5
11	The cysteinyl leukotriene 3 receptor regulates expansion of IL-25–producing airway brush cells leading to type 2 inflammation. Science Immunology, 2018, 3, .	11.9	125
12	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Research, 2017, 77, 1261-1270.	0.9	210
13	Leukotrienes provide an NFAT-dependent signal that synergizes with IL-33 to activate ILC2s. Journal of Experimental Medicine, 2017, 214, 27-37.	8.5	132
14	Resolution of a human mast cell development conundrum. Blood, 2017, 130, 1777-1778.	1.4	5
15	CysLT1 Receptor Is Protective against Oxidative Stress in a Model of Irritant-Induced Asthma. Journal of Immunology, 2016, 197, 266-277.	0.8	20
16	Leukotriene E ₄ elicits respiratory epithelial cell mucin release through the G-protein–coupled receptor, GPR99. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6242-6247.	7.1	99
17	Expression profiling of constitutive mast cells reveals a unique identity within the immune system. Nature Immunology, 2016, 17, 878-887.	14.5	293
18	B Cells Regulate CD4+ T Cell Responses to Papain following B Cell Receptor–Independent Papain Uptake. Journal of Immunology, 2014, 193, 529-539.	0.8	11

K FRANK AUSTEN

#	Article	IF	CITATIONS
19	Identification of GPR99 Protein as a Potential Third Cysteinyl Leukotriene Receptor with a Preference for Leukotriene E4 Ligand. Journal of Biological Chemistry, 2013, 288, 10967-10972.	3.4	156
20	The leukotriene E4 puzzle: Finding the missing pieces and revealing the pathobiologic implications. Journal of Allergy and Clinical Immunology, 2009, 124, 406-414.	2.9	93
21	The cysteinyl leukotrienes: Where do they come from? What are they? Where are they going?. Nature Immunology, 2008, 9, 113-115.	14.5	40
22	Doing What I Like. Annual Review of Immunology, 2008, 26, 1-28.	21.8	2
23	Additional functions for the cysteinyl leukotrienes recognized through studies of inflammatory processes in null strains. Prostaglandins and Other Lipid Mediators, 2007, 83, 182-187.	1.9	10
24	Cysteinyl Leukotrienes Regulate Th2 Cell-Dependent Pulmonary Inflammation. Journal of Immunology, 2006, 176, 4440-4448.	0.8	132
25	Targeted Gene Disruption Reveals the Role of the Cysteinyl Leukotriene 2 Receptor in Increased Vascular Permeability and in Bleomycin-induced Pulmonary Fibrosis in Mice. Journal of Biological Chemistry, 2004, 279, 46129-46134.	3.4	134
26	Acceptance of the Kober Medal It only gets better. Journal of Clinical Investigation, 2004, 114, 1177-1177.	8.2	2
27	Targeted Gene Disruption Reveals the Role of Cysteinyl Leukotriene 1 Receptor in the Enhanced Vascular Permeability of Mice Undergoing Acute Inflammatory Responses. Journal of Biological Chemistry, 2002, 277, 20820-20824.	3.4	119
28	gp49B1-αvβ3 interaction inhibits antigen-induced mast cell activation. Nature Immunology, 2001, 2, 436-442.	14.5	84
29	Attenuated Zymosan-induced Peritoneal Vascular Permeability and IgE-dependent Passive Cutaneous Anaphylaxis in Mice Lacking Leukotriene C4 Synthase. Journal of Biological Chemistry, 2001, 276, 22608-22613.	3.4	133
30	Mast Cell Mediation of Muscle and Pulmonary Injury Following Hindlimb Ischemia–Reperfusion. Journal of Histochemistry and Cytochemistry, 2001, 49, 1055-1056.	2.5	26
31	The Presence of v-abl-transformed V3 Mast Cells in the Lungs Augments Pulmonary Vascular Permeability to Acid Aspiration. Journal of Histochemistry and Cytochemistry, 2001, 49, 793-794.	2.5	Ο
32	Increased Severity of Local and Systemic Anaphylactic Reactions in Gp49b1-Deficient Mice. Journal of Experimental Medicine, 2001, 194, 227-234.	8.5	62
33	The Diverse Roles of Mast Cells. Journal of Experimental Medicine, 2001, 194, F1-F6.	8.5	180
34	T Helper Cell Type 2 Cytokine–Mediated Comitogenic Responses and Ccr3 Expression during Differentiation of Human Mast Cells in Vitro. Journal of Experimental Medicine, 1999, 190, 267-280.	8.5	323
35	The Biochemical, Molecular, and Genomic Aspects of Leukotriene C4 Synthase. Proceedings of the Association of American Physicians, 1999, 111, 537-546.	2.0	32
36	Phospholipase A2 Enzymes in Eicosanoid Generation. Proceedings of the Association of American Physicians, 1999, 111, 516-524.	2.0	61

K FRANK AUSTEN

#	Article	IF	CITATIONS
37	Molecular Cloning of the Gene for Mouse Leukotriene-C4 Synthase. FEBS Journal, 1997, 248, 807-813.	0.2	17
38	Molecular Cloning, Expression and Characterization of Mouse Leukotriene C4 Synthase. FEBS Journal, 1996, 238, 606-612.	0.2	34
39	Cytokine Regulation of Mast Cell Protease Phenotype and Arachidonic Acid Metabolism. Annals of the New York Academy of Sciences, 1994, 744, 84-98.	3.8	5
40	Acute and chronic suppression of leukotriene B4 synthesis EX vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis and Rheumatism, 1992, 35, 376-384.	6.7	99
41	Inhibition of Leukotriene B ₄ synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis and Rheumatism, 1990, 33, 1149-1155.	6.7	63
42	Influence of the Fibroblast Environment on the Structure of Mast Cell Proteoglycans. Annals of the New York Academy of Sciences, 1989, 556, 233-244.	3.8	12
43	Different Mast Cell Mediators Produced by Different Mast Cell Phenotypes. Novartis Foundation Symposium, 1989, 147, 36-52.	1.1	2
44	Perspectives on Additional Areas for Research in Leukotrienes. Annals of the New York Academy of Sciences, 1988, 524, xi-xxv.	3.8	7
45	Cyclosporin A Treatment of Refractory Rheumatoid Arthritis. Arthritis and Rheumatism, 1987, 30, 11-17.	6.7	134
46	2,000-Centigray total lymphoid irradiation for refractory rheumatoid arthritis. Arthritis and Rheumatism, 1987, 30, 980-987.	6.7	15
47	Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arthritis and Rheumatism, 1987, 30, 988-997.	6.7	207
48	Specific release of proteoglycans from human natural killer cells during target lysis. Nature, 1985, 318, 289-291.	27.8	148
49	Total lymphoid irradiation therapy in refractory rheumatoid arthritis. Arthritis and Rheumatism, 1984, 27, 481-488.	6.7	62
50	The Complement Components of the Major Histocompatibility Locu. Critical Reviews in Biochemistry, 1984, 16, 1-19.	7.5	37
51	The role of antibody in the activation of the alternative complement pathway. Seminars in Immunopathology, 1983, 6, 361-371.	4.0	92
52	Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature, 1981, 293, 103-108.	27.8	495
53	The Natural Modulation of the Amplification Phase of Complement Activation. Immunological Reviews, 1976, 32, 12-25.	6.0	16
54	Intraarticular activation of the complement system in patients with juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1976, 19, 161-168.	6.7	15

K FRANK AUSTEN

#	Article	IF	CITATIONS
55	A Chemotactic Receptor for VAL(ALA)-GLY-SER-GLU on Human Eosinophil Polymorphonuclear Leukocytes. Immunological Investigations, 1976, 5, 469-479.	0.8	14
56	THE MODULATING INFLUENCE OF CYCLIC NUCLEOTIDES UPON LYMPHOCYTE-MEDIATED CYTOTOXICITY. Journal of Experimental Medicine, 1973, 138, 381-393.	8.5	180
57	The Complement System of Man. New England Journal of Medicine, 1972, 287, 545-549.	27.0	55
58	The Complement System of Man. New England Journal of Medicine, 1972, 287, 489-495.	27.0	279
59	The Complement System of Man. New England Journal of Medicine, 1972, 287, 642-646.	27.0	88
60	A NEUTROPHIL-IMMOBILIZING FACTOR DERIVED FROM HUMAN LEUKOCYTES. Journal of Experimental Medicine, 1972, 136, 1564-1580.	8.5	154
61	The Complement System of Man. New England Journal of Medicine, 1972, 287, 592-596.	27.0	68
62	IGE AND IGGA ANTIBODY-MEDIATED RELEASE OF HISTAMINE FROM RAT PERITONEAL CELLS. Journal of Experimental Medicine, 1971, 133, 772-784.	8.5	54
63	Chemical Mediators of Immediate Hypersensitivity. Hospital Practice (1995), 1971, 6, 79-89.	1.0	10
64	MODULATION OF FUNCTION OF THE ACTIVATED FIRST COMPONENT OF COMPLEMENT BY A FRAGMENT DERIVED FROM SERUM. Journal of Experimental Medicine, 1971, 134, 1466-1484.	8.5	24
65	IGE AND IGGA ANTIBODY-MEDIATED RELEASE OF HISTAMINE FROM RAT PERITONEAL CELLS. Journal of Experimental Medicine, 1971, 133, 752-771.	8.5	87
66	AN EOSINOPHIL LEUKOCYTE CHEMOTACTIC FACTOR OF ANAPHYLAXIS. Journal of Experimental Medicine, 1971, 133, 602-619.	8.5	282
67	Total hemolytic complement (CH50) and second component of complement (C′2hu) activity in serum and synovial fluid. Arthritis and Rheumatism, 1965, 8, 219-232.	6.7	76